Human IL-22 Recombinant Rabbit mAb (S-3604)

Interleukin-22 (IL-22) is a 20 kDa α-helical cytokine of the IL-10 family that is produced chiefly by activated innate lymphoid cells, Th17, Th22 and γδ T cells, signals exclusively through a heterodimeric receptor complex of IL-22R1 and IL-10R2 to activate STAT3 and, to a lesser extent, STAT1 and STAT5, and functions as a frontline defender of barrier organs by up-regulating antimicrobial peptides (e.g., β-defensins, RegIIIγ), mucins and tight-junction proteins, stimulating epithelial proliferation and survival, while simultaneously suppressing inflammatory cytokine release from tissue-resident immune cells, thereby orchestrating tissue repair, containment of commensal microbes and protection against extracellular bacterial and fungal pathogens; however, its dysregulation contributes to psoriasis, inflammatory bowel disease, fibrosis and certain cancers, making it a key target for therapeutic modulation.